Abbott to ask FDA panel for expanded approval of carotid stent

An FDA panel will review an Abbott Labs carotid stent Wednesday for use in less-risky patients. The Acculink carotid stent has already been approved for higher-risk patients, but Abbott wants the flexibility to market the stent for patients with fewer risks.

In a 2,502 patient Abbott-funded study whose results were released in preparation for the panel meeting, the stent procedure didn't create more risks than a carotid endarterectomy surgery, where the fatty deposits in the carotid artery are scraped out. In October, the Archives of Neurology published findings that neck stents did create a greater chance of stroke and death.

Abbott spokesman Jonathon Hamilton said if FDA approves the wider use, the company will also seek expanded reimbursement coverage through Medicare, Reuters adds.

- see the Reuters coverage
- get the panel documents here

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.